Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections

被引：3

作者：

Wu, Gary ^{[1
]}

Truong, James ^{[1
]}

Lee, Spencer ^{[1
]}

Elnadoury, Ola ^{[1
]}

Kuan, William ^{[1
]}

Abraham, Teena ^{[1
]}

Wu, Anh ^{[2
]}

Liu, Mei ^{[3
]}

机构：

[1] New York Methodist Hosp, Dept Pharm, Brooklyn, NY 11215 USA

[2] Mt Sinai Roosevelt, Dept Pharm, New York, NY 10019 USA

[3] Bellevue Hosp Ctr, Dept Pharm, New York, NY 10016 USA

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2015年 / 13卷 / 04期

关键词：

acute bacterial skin and skin structure infections; complicated skin and skin structure infections; glycopeptides; lipoglycopeptides; oritavancin; SOFT-TISSUE INFECTIONS; STAPHYLOCOCCUS-AUREUS; UNITED-STATES; VANCOMYCIN; PHARMACOKINETICS; EPIDEMIOLOGY; RESISTANT; DIAGNOSIS; SAFETY;

D O I：

10.1586/14787210.2015.1012498

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Oritavancin, a lipoglycopeptide antibiotic, recently received US FDA approval for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI). Oritavancin, unlike other intravenous antibiotics that are currently available for the treatment of ABSSSI (e.g., vancomycin, daptomycin, telavancin, dalbavancin), offers the option of a single-dose complete regimen. The dosing schedule of oritavancin eliminates the need for an indwelling catheter and introduces the possibility of avoidance of a hospital admission; although, treatment in non-hospital settings has not been adequately evaluated in clinical trials. The availability of oritavancin adds another agent to our antibiotic armamentarium providing dosing flexibility and an alternative treatment option for treatment of ABSSSI caused by susceptible bacteria, including methicillin-resistant Staphylococcus aureus.

引用

页码：409 / 416

页数：8

共 27 条

[1]

Allen Norris E., 2010, Anti-Infective Agents in Medicinal Chemistry, V9, P23

[2] Hospitalist Perspective on the Treatment of Skin and Soft Tissue Infections [J].

Amin, Alpesh N. ;

Cerceo, Elizabeth A. ;

Deitelzweig, Steven B. ;

Pile, James C. ;

Rosenberg, David J. ;

Sherman, Bradley M. .

MAYO CLINIC PROCEEDINGS, 2014, 89 (10) :1436-1451

[3]

[Anonymous], 2014, Dalvance® [package insert]

[4]

[Anonymous], 2014, VIB PACK INS

[5] Effect of polysorbate 80 on oritavancin binding to plastic surfaces: Implications for susceptibility testing [J].

Arhin, Francis F. ;

Sarmiento, Ingrid ;

Belley, Adam ;

McKay, Geoffrey A. ;

Draghi, Deborah C. ;

Grover, Parveen ;

Sahm, Daniel F. ;

Parr, Thomas R., Jr. ;

Moeck, Gregory .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (05) :1597-1603

[6] Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates [J].

Arhin, Francis F. ;

Draghi, Deborah C. ;

Pillar, Chris M. ;

Parr, Thomas R., Jr. ;

Moeck, Gregory ;

Sahm, Daniel F. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (11) :4762-4771

[7] Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin [J].

Arhin, Francis F. ;

Sarmiento, Ingrid ;

Parr, Thomas R., Jr. ;

Moeck, Gregory .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (04) :868-870

[8] Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects [J].

Bhavnani, SM ;

Owen, JS ;

Loutit, JS ;

Porter, SB ;

Ambrose, PG .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 50 (02) :95-102

[9]

Briefing document for the anti-infective drug advisory committee, NOV OR DIPH INJ TREA

[10] Pharmacology and the Treatment of Complicated Skin and Skin-Structure Infections [J].

Chambers, Henry F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (23) :2238-2239

← 1 2 3 →